Regis [RGS] vs Medifast [MED] Detailed Stock Comparison
Regis
NASDAQ
Loading...
Medifast
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Regis wins in 10 metrics, Medifast wins in 8 metrics, with 0 ties. Regis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Regis | Medifast | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 0.68 | 42.39 | Regis |
| Price-to-Book Ratio | 0.39 | 0.67 | Regis |
| Debt-to-Equity Ratio | 188.97 | 6.05 | Medifast |
| PEG Ratio | -11.20 | -0.32 | Regis |
| EV/EBITDA | 17.52 | -0.22 | Medifast |
| Profit Margin (TTM) | 58.79% | 0.76% | Regis |
| Operating Margin (TTM) | 7.59% | -1.01% | Regis |
| EBITDA Margin (TTM) | 7.59% | N/A | N/A |
| Return on Equity | 96.56% | 1.73% | Regis |
| Return on Assets (TTM) | 2.25% | 2.88% | Medifast |
| Free Cash Flow (TTM) | $12.45M | $17.02M | Medifast |
| 1-Year Return | 8.39% | -24.13% | Regis |
| Price-to-Sales Ratio (TTM) | 0.34 | 0.32 | Medifast |
| Enterprise Value | $405.86M | $-5.94M | Regis |
| EV/Revenue Ratio | 1.93 | -0.01 | Medifast |
| Gross Profit Margin (TTM) | 36.70% | 72.61% | Medifast |
| Revenue per Share (TTM) | $89 | $44 | Regis |
| Earnings per Share (Diluted) | $43.67 | $0.33 | Regis |
| Beta (Stock Volatility) | 1.77 | 0.88 | Medifast |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Regis vs Medifast Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Regis | 0.44% | 3.28% | 22.89% | 27.61% | 69.32% | 24.65% |
| Medifast | 2.34% | 2.04% | 0.21% | -4.05% | 7.12% | -19.09% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Regis | 8.39% | 35.69% | -78.87% | -88.68% | 55.03% | -18.76% |
| Medifast | -24.13% | -87.77% | -91.52% | -51.52% | -47.23% | 246.29% |
Performance & Financial Health Analysis: Regis vs Medifast
| Metric | RGS | MED |
|---|---|---|
| Market Information | ||
| Market Cap | $74.66M | $155.35M |
| Market Cap Category | Micro cap | Micro cap |
| 10 Day Avg. Volume | 10,476 | 147,157 |
| 90 Day Avg. Volume | 22,679 | 150,239 |
| Last Close | $29.58 | $13.99 |
| 52 Week Range | $15.00 - $30.29 | $11.57 - $21.98 |
| % from 52W High | -2.34% | -36.35% |
| All-Time High | $465.40 (Oct 28, 2019) | $336.99 (May 24, 2021) |
| % from All-Time High | -93.64% | -95.85% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.22% | -0.37% |
| Quarterly Earnings Growth | 0.28% | -0.37% |
| Financial Health | ||
| Profit Margin (TTM) | 0.59% | 0.01% |
| Operating Margin (TTM) | 0.08% | -0.01% |
| Return on Equity (TTM) | 0.97% | 0.02% |
| Debt to Equity (MRQ) | 188.97 | 6.05 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $76.20 | $21.04 |
| Cash per Share (MRQ) | $6.96 | $15.84 |
| Operating Cash Flow (TTM) | $13.74M | $4.15M |
| Levered Free Cash Flow (TTM) | $10.93M | $10.69M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | $0.00 |
Valuation & Enterprise Metrics Analysis: Regis vs Medifast
| Metric | RGS | MED |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 0.68 | 42.39 |
| Forward P/E | -11.20 | 46.63 |
| PEG Ratio | -11.20 | -0.32 |
| Price to Sales (TTM) | 0.34 | 0.32 |
| Price to Book (MRQ) | 0.39 | 0.67 |
| Market Capitalization | ||
| Market Capitalization | $74.66M | $155.35M |
| Enterprise Value | $405.86M | $-5,940,794 |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.93 | -0.01 |
| Enterprise to EBITDA | 17.52 | -0.22 |
| Risk & Other Metrics | ||
| Beta | 1.77 | 0.88 |
| Book Value per Share (MRQ) | $76.20 | $21.04 |
Financial Statements Comparison: Regis vs Medifast
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RGS | MED |
|---|---|---|
| Revenue/Sales | $60.40M | $115.73M |
| Cost of Goods Sold | $38.23M | $31.48M |
| Gross Profit | $22.16M | $84.25M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $7.29M | $-1.26M |
| EBITDA | $9.77M | $2.02M |
| Pre-Tax Income | $2.98M | $526,000 |
| Income Tax | $-115.41M | $1.30M |
| Net Income (Profit) | $116.49M | $-772,000 |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RGS | MED |
|---|---|---|
| Cash & Equivalents | $16.96M | $91.72M |
| Total Current Assets | $50.48M | $213.52M |
| Total Current Liabilities | $101.69M | $60.60M |
| Long-Term Debt | $288.97M | $8.45M |
| Total Shareholders Equity | $185.62M | $210.96M |
| Retained Earnings | $101.97M | $176.01M |
| Property, Plant & Equipment | $229.86M | $46.32M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RGS | MED |
|---|---|---|
| Operating Cash Flow | $5.63M | $2.62M |
| Capital Expenditures | N/A | $-1.52M |
| Free Cash Flow | $6.23M | $1.88M |
| Debt Repayment | $-3.60M | N/A |
| Common Stock Repurchase | N/A | $-369,000 |
Short Interest & Institutional Ownership Analysis
| Metric | RGS | MED |
|---|---|---|
| Shares Short | 113,166 | 2.34M |
| Short Ratio | 4.85 | 14.97 |
| Short % of Float | 0.05% | 0.22% |
| Average Daily Volume (10 Day) | 10,476 | 147,157 |
| Average Daily Volume (90 Day) | 22,679 | 150,239 |
| Shares Outstanding | 2.44M | 10.94M |
| Float Shares | 2.17M | 9.15M |
| % Held by Insiders | 0.14% | 0.03% |
| % Held by Institutions | 0.26% | 0.80% |
Dividend Analysis & Yield Comparison: Regis vs Medifast
| Metric | RGS | MED |
|---|---|---|
| Last 12-Month Dividend | $0.00 | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $0.00 | $2.74 |
| 3-Year Avg Dividend Yield | N/A | 1.43% |
| 3-Year Total Dividends | $0.00 | $8.22 |
| Ex-Dividend Date | N/A | Jun 26, 2023 |